Previous Close | 80.44 |
Open | 80.78 |
Bid | 78.72 x 0 |
Ask | 78.76 x 0 |
Day's Range | 78.46 - 81.06 |
52 Week Range | 61.28 - 83.34 |
Volume | |
Avg. Volume | 913,369 |
Market Cap | 38.848B |
Beta (5Y Monthly) | 0.70 |
PE Ratio (TTM) | 41.67 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 0.24 (0.30%) |
Ex-Dividend Date | May 14, 2024 |
1y Target Est | N/A |
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: O
GENEVA, May 13, 2024--Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales in Contact Lenses and Ocular Health
GENEVA, May 08, 2024--Alcon Announces Results of 2024 Annual General Meeting